Xeris Biopharma Holdings, Inc. Common Stock (XERS) Stock
Key stats
- Market cap
- $3.02B
- Price / Earnings ratio
- -445.2x
- EPS (TTM)
- -$0.04
- Volume
- Loading
- 52-week high
- $16.11
- 52-week low
- $5.25
Source: third-party data provider, as of November 13, 2026
Compare with XERS
Recent news

Why Did AAPL, XERS, ZETA Stocks Jump To 52-Week Highs Today?
Why Did AAPL, XERS, ZETA Stocks Jump To 52-Week Highs Today?
XERS

XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
XERS

Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
XERS

Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
XERS
Technical indicators
- RSI 14
- 85.12
- MACD 12/26/9
- 1.49
- EMA 9 of MACD
- 0.88
- MACD histogram
- 0.61
- SMA 50
- $10.08
- Price above SMA 50
- EMA 50
- $10.68
- Price above EMA 50
- SMA 200
- $7.74
- Price above SMA 200
- EMA 200
- $8.33
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.01 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Why Did AAPL, XERS, ZETA Stocks Jump To 52-Week Highs Today?
Why Did AAPL, XERS, ZETA Stocks Jump To 52-Week Highs Today?
XERS

XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
XERS

Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week?
XERS

Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
XERS

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
XERS

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
XERS

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
XERS

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
XERS

Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
XERS

Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
XERS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Xeris Biopharma Holdings, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John P. Shannon | Chairman & CEO | 1962 |
| Mr. Kevin McCulloch | President & COO | 1964 |
| Mr. Steven M. Pieper | Chief Financial Officer | 1977 |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 1964 |
| Dr. Anh T. Nguyen M.B.A., M.D. | Chief Medical Officer | 1975 |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | — |
| Ms. Kendal Korte | Senior Vice President of Human Resources | — |
| Joshua Bennett | Vice President of Strategy & Business Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 85.12
- MACD 12/26/9
- 1.49
- EMA 9 of MACD
- 0.88
- MACD histogram
- 0.61
- SMA 50
- $10.08
- Price above SMA 50
- EMA 50
- $10.68
- Price above EMA 50
- SMA 200
- $7.74
- Price above SMA 200
- EMA 200
- $8.33
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $12.00
- Average
- $17.00
- High
- $21.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.7 | +50.3 | ||||||||||
| 2022 | -24.9 | +11.7 | +7.6 | -5.4 | -10.2 | -29.0 | -5.3 | +10.6 | -9.3 | +2.6 | -5.7 | -14.2 |
| 2023 | +10.7 | +13.1 | +14.8 | +24.2 | +4.9 | +0.0 | +2.4 | -15.6 | -21.5 | +4.6 | -0.5 | +24.3 |
| 2024 | +8.4 | +22.7 | -30.5 | -18.2 | +29.1 | -8.2 | +14.3 | +15.6 | +10.0 | +15.4 | +1.5 | +0.3 |
| 2025 | +2.9 | +6.7 | +48.8 | -10.0 | +10.3 | -7.5 | +9.2 | +45.5 | +2.8 | +21.1 | -27.5 | +12.8 |
| 2026 | +0.1 | -16.8 | -3.7 | +1.5 | -1.9 | +30.5 | +1.0 | +3.8 | +13.4 | +15.8 | +62.4 |



